Abivax SA expected to post a loss of €1.28 a share - Earnings Preview

Reuters03-20

<a href="https://laohu8.com/S/AAVXF">Abivax SA</a> <abvx.oq> expected to post a loss of €1.28 a share - Earnings Preview </abvx.oq>

Abivax SA ABVX.OQ, ABVX.O is expected to report resultson March 23 for the period ending December 31 2025
The Paris Ile-de-france-based company is expected to report revenue of €1.435 million, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Abivax SA is for a loss of €1.28 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Abivax SA is $142.00, about 15.4% above its last closing price of $123.03

Previous quarterly performance (using preferred earnings measure in euros).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Sep. 30 2025	-0.73	-0.71	-2.10	Missed	-197.2
Jun. 30 2025	-0.80	-0.79	-0.76	Beat	4.4
Mar. 31 2025	-0.83	-0.77	-0.83	Missed	-8.3
Dec. 31 2024		-1.11
Sep. 30 2024		-0.68
Jun. 30 2024		-1.28
Mar. 31 2024		-0.74
Dec. 31 2023		-0.41

This summary was machine generated March 20 at 07:32 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620783640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 15:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620783640","market":"fut","top_or_hot":-1,"title":"Abivax SA  expected to post a loss of €1.28 a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AAVXF\">Abivax SA</a> <abvx.oq> expected to post a loss of €1.28 a share - Earnings Preview </abvx.oq></title></head><body><ul><li><p>Abivax SA <span>ABVX.OQ</span>, <span>ABVX.O</span> is expected to  report resultson March 23 for the period ending December 31 2025</p></li><li><p>The Paris Ile-de-france-based  company is expected to report revenue of €1.435 million, according to the mean estimate from 4 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Abivax SA is for a loss of €1.28 per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy,\" no \"hold\" and 1 \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Abivax SA is $142.00, about 15.4% above its last closing price of $123.03</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in euros). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Sep. 30 2025</p></td><td><p>-0.73</p></td><td><p>-0.71</p></td><td><p>-2.10</p></td><td><p>Missed</p></td><td><p>-197.2</p></td></tr><tr><td><p>Jun. 30 2025</p></td><td><p>-0.80</p></td><td><p>-0.79</p></td><td><p>-0.76</p></td><td><p>Beat</p></td><td><p>4.4</p></td></tr><tr><td><p>Mar. 31 2025</p></td><td><p>-0.83</p></td><td><p>-0.77</p></td><td><p>-0.83</p></td><td><p>Missed</p></td><td><p>-8.3</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td></td><td><p>-1.11</p></td><td></td><td></td><td></td></tr><tr><td><p>Sep. 30 2024</p></td><td></td><td><p>-0.68</p></td><td></td><td></td><td></td></tr><tr><td><p>Jun. 30 2024</p></td><td></td><td><p>-1.28</p></td><td></td><td></td><td><p></p></td></tr><tr><td><p>Mar. 31 2024</p></td><td></td><td><p>-0.74</p></td><td></td><td></td><td></td></tr><tr><td><p>Dec. 31 2023</p></td><td></td><td><p>-0.41</p></td><td></td><td></td><td></td></tr></tbody></table><p>This summary was machine generated March 20 at 07:32 GMT.  All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abivax SA  expected to post a loss of €1.28 a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbivax SA  expected to post a loss of €1.28 a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 15:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/AAVXF\">Abivax SA</a> <abvx.oq> expected to post a loss of €1.28 a share - Earnings Preview </abvx.oq></title></head><body><ul><li><p>Abivax SA <span>ABVX.OQ</span>, <span>ABVX.O</span> is expected to  report resultson March 23 for the period ending December 31 2025</p></li><li><p>The Paris Ile-de-france-based  company is expected to report revenue of €1.435 million, according to the mean estimate from 4 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Abivax SA is for a loss of €1.28 per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy,\" no \"hold\" and 1 \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Abivax SA is $142.00, about 15.4% above its last closing price of $123.03</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in euros). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Sep. 30 2025</p></td><td><p>-0.73</p></td><td><p>-0.71</p></td><td><p>-2.10</p></td><td><p>Missed</p></td><td><p>-197.2</p></td></tr><tr><td><p>Jun. 30 2025</p></td><td><p>-0.80</p></td><td><p>-0.79</p></td><td><p>-0.76</p></td><td><p>Beat</p></td><td><p>4.4</p></td></tr><tr><td><p>Mar. 31 2025</p></td><td><p>-0.83</p></td><td><p>-0.77</p></td><td><p>-0.83</p></td><td><p>Missed</p></td><td><p>-8.3</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td></td><td><p>-1.11</p></td><td></td><td></td><td></td></tr><tr><td><p>Sep. 30 2024</p></td><td></td><td><p>-0.68</p></td><td></td><td></td><td></td></tr><tr><td><p>Jun. 30 2024</p></td><td></td><td><p>-1.28</p></td><td></td><td></td><td><p></p></td></tr><tr><td><p>Mar. 31 2024</p></td><td></td><td><p>-0.74</p></td><td></td><td></td><td></td></tr><tr><td><p>Dec. 31 2023</p></td><td></td><td><p>-0.41</p></td><td></td><td></td><td></td></tr></tbody></table><p>This summary was machine generated March 20 at 07:32 GMT.  All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4080DW:1","article_id":"2620783640","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620783640","pubTimestamp":1773991952,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Abivax SA  expected to post a loss of 1.28 a share - Earnings Preview Abivax SA ABVX.OQ, ABVX.O is expected to  report resultson March 23 for the period ending December 31 2025The Paris Ile-de-france-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A.","BK4139":"生物科技"},"translate_title":"Abivax SA预计每股亏损1.28欧元-收益预览","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":0.9},"content_text":"Abivax SA  expected to post a loss of €1.28 a share - Earnings Preview Abivax SA ABVX.OQ, ABVX.O is expected to  report resultson March 23 for the period ending December 31 2025The Paris Ile-de-france-based  company is expected to report revenue of €1.435 million, according to the mean estimate from 4 analysts, based on LSEG data.LSEG's mean analyst estimate for Abivax SA is for a loss of €1.28 per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy,\" no \"hold\" and 1 \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Abivax SA is $142.00, about 15.4% above its last closing price of $123.03Previous quarterly performance (using preferred earnings measure in euros). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Sep. 30 2025-0.73-0.71-2.10Missed-197.2Jun. 30 2025-0.80-0.79-0.76Beat4.4Mar. 31 2025-0.83-0.77-0.83Missed-8.3Dec. 31 2024-1.11Sep. 30 2024-0.68Jun. 30 2024-1.28Mar. 31 2024-0.74Dec. 31 2023-0.41This summary was machine generated March 20 at 07:32 GMT.  All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620783640","isCrawlerRequest":true}